European equities traded in the US as American depositary receipts were nudging marginally lower late Wednesday morning with the S&P Europe Select ADR Index declining 0.09% to 1,399.82.
From continental Europe, the gainers were led by biopharmaceutical company Genfit (GNFT) and biotech firm Evaxion Biotech (EVAX), which rose 3.7% each. They were followed by semiconductor company Sequans Communications (SQNS) and telecommunications operator Telefonica (TEF), which increased 3.3% and 2.9% respectively.
The decliners from continental Europe were led by furniture maker Natuzzi (NTZ) and medical device maker EDAP TMS (EDAP), which dropped 6.2% and 1.5% respectively. They were followed by Ericsson (ERIC) and telecommunications companies VEON (VEON), which fell 1.3% and 0.9% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which soared 61.2%, followed by biotech firm Trinity Biotech (TRIB) and software firm Endava (DAVA), which increased 3.8% and 2.9% respectively, while medical device maker Smith & Nephew (SNN) was up 1.7%.
The decliners from the UK and Ireland were led by biopharmaceutical companies NuCana (NCNA) and TC Biopharm (TCBP), which fell 5.3% and 0.8% respectively. They were followed by biopharmaceutical company Akari Therapeutics (AKTX), which was down 0.9%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。